BLAINTRAVITREALINJECTABLEPriority Review
Approved
Jan 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
28
Data completeness
5/8 — Partial
Priority Review
VABYSMO (faricimab) by Roche. Approved for diabetic macular edema, neovascular age-related macular degeneration. First approved in 2022.
Drug data last refreshed 6d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VABYSMO (faricimab) is a bispecific antibody (BSAB) developed by Roche and approved by the FDA on January 28, 2022, for intravitreal injection. It treats multiple retinal conditions including diabetic macular edema, neovascular age-related macular degeneration, retinal vein occlusion, diabetic retinopathy, choroidal neovascularization, polypoidal choroidal vasculopathy, and radiation retinopathy. As a bispecific antibody, faricimab simultaneously targets two pathways—angiopoietin-2 and vascular endothelial growth factor (VEGF)—offering a dual mechanism approach to address both vascular instability and neovascularization.
$0.0BPart D
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on VABYSMO at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.